IMMUNIC IMUX 深 沪
已收盘 05-08 16:00:00 美东时间
11.63
-0.120
-1.02%
华盛通- 最 高12.0871
- 今 开11.64
- 成交量 22.15万股
- 最 低 11.25
- 昨 收 11.75
- 总市值 1.58亿
- 52周最高 15.10
- 市盈率 静 --
- 换手率 1.63%
- 52周最低 5.062
- 委 比 -66.67%
- 总股本 1362.15万
- 历史最高 289.90
- 量 比 0.68
- 振 幅 7.12%
- 历史最低 5.062
- 每 手 1
- 风险率 1.81%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股机会日报 | 太意外！美官员突然宣布：敌对行动已结束；五角大楼与谷歌、英伟达、SpaceX等签署协议！
太意外！美官员突然宣布：敌对行动已结束；五角大楼：已与SpaceX、谷歌和英伟达签署协议！获批合法军事作战用途；苹果盘前涨近4%，营收指引意外强劲>>
05-01 20:09
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
HC Wainwright & Co. Maintains Buy on Immunic, Raises Price Target to $22
HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and raises the price target from $5 to $22.
04-30 18:43
Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy
Immunic appoints Michael Panzara as CMO, granting inducement equity award as he takes charge of clinical and regulatory strategy.
04-28 18:38
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
– Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Globa...
04-28 18:30
Immunic announces 1-for-10 reverse stock split
Immunic (IMUX) will effect a reverse stock split of its outstanding shares of common stock, effective April 27, 2026. The reverse stock split is primarily intended to allow Immunic to meet its contrac...
04-23 21:02
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Com...
04-23 20:00
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
Stifel Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $2.5
Stifel analyst Paul Matteis initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $2.5.
04-17 19:07
This Parsons Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings and analysts' views on PSN.
04-15 21:16
